Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, has announced, in response to shareholder inquiries, that the data safety monitoring board (DSMB) has made an unblinded review of the safety data for the company’s ongoing international Phase III GBM trial, and has recommended that the trial continue as planned.
Subscribe to our email newsletter
The DSMB’s review of the efficacy data is still pending.
Northwest Biotherapeutics chief technical officer Dr. Marnix Bosch noted the company is pleased with the recommendation of the DSMB to continue the trial as planned.
"This is an important step in the ongoing progress of our Phase III trial," Dr Bosch added.